• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor
    Hero Background

    Chorea Market

    ID: MRFR/HC/3782-HCR
    85 Pages
    Rahul Gotadki
    October 2025

    Chorea Market Research Information by Type (Huntington’s disease, Sydenham’s chorea, Drug-induced chorea), Treatment (Medical Care, Surgical Care), Distribution Channel (Hospitals, Diagnostic Centers, Drug Stores, Pharmacies) – forecast till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Chorea Market Infographic
    Purchase Options

    Chorea Market Summary

    The global chorea market is projected to grow from 0.8 USD billion in 2024 to 1.67 USD billion by 2035.

    Key Market Trends & Highlights

    Chorea Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 6.93% from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 1.67 USD billion, indicating robust growth.
    • In 2024, the market is valued at 0.8 USD billion, reflecting the current demand for chorea treatments.
    • Growing adoption of innovative therapies due to increasing awareness of chorea is a major market driver.

    Market Size & Forecast

    2024 Market Size 0.8 (USD Billion)
    2035 Market Size 1.67 (USD Billion)
    CAGR (2025-2035) 6.93%

    Major Players

    Medtronic plc., Boston Scientific Corporation, ALEVA NEUROTHERAPEUTICS SA, Pfizer Inc., GlaxoSmithKline plc., Bausch Health Companies Inc., Teva Pharmaceutical Industries Ltd., LivaNova PLC, H. Lundbeck A/S, Ipsen, Alnylam Pharmaceuticals Inc., RespireRx Pharmaceuticals Inc., Vertex Pharmaceuticals, Inc., Prana Biotechnology Ltd., SOM Innovation Biotech S.A.

    Chorea Market Drivers

    Rising Research Funding

    The Global Chorea Market Industry is likely to experience growth fueled by increased funding for research and development. Governments and private organizations are investing in studies aimed at understanding the pathophysiology of chorea and identifying potential therapeutic targets. This influx of funding is expected to accelerate the development of novel treatments and diagnostic tools. For example, initiatives aimed at enhancing genetic research may lead to breakthroughs in personalized medicine for chorea patients. As research progresses, the market could see a surge in innovative solutions that address unmet medical needs, further driving market expansion.

    Market Growth Projections

    The Global Chorea Market Industry is projected to experience substantial growth over the next decade. The market is expected to reach 0.8 USD Billion in 2024 and is forecasted to grow to 1.67 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate (CAGR) of 6.93% from 2025 to 2035. Such projections indicate a robust demand for therapeutic options and highlight the increasing recognition of chorea as a critical area of focus within neurology. The anticipated market expansion reflects both the rising prevalence of chorea and the ongoing advancements in treatment and diagnostic methodologies.

    Enhanced Diagnostic Techniques

    The Global Chorea Market Industry is poised for growth due to enhanced diagnostic techniques that facilitate earlier and more accurate identification of chorea. Advances in imaging technologies and genetic testing are enabling healthcare providers to diagnose chorea more effectively. For instance, the use of advanced neuroimaging can help differentiate chorea from other movement disorders, leading to timely interventions. As diagnostic accuracy improves, it is anticipated that more patients will be identified and treated, thereby expanding the market. This trend underscores the importance of integrating cutting-edge technology into clinical practice to optimize patient care.

    Growing Awareness and Education

    The Global Chorea Market Industry is also influenced by growing awareness and education regarding chorea and its associated disorders. Healthcare professionals are increasingly recognizing the importance of early diagnosis and intervention, which can significantly improve patient outcomes. Public health campaigns aimed at educating the general population about the symptoms and risks of chorea are likely to enhance early detection rates. As awareness increases, more patients may seek medical help, contributing to market growth. This trend is expected to be particularly pronounced in regions with previously limited access to information about chorea.

    Increasing Prevalence of Chorea

    The Global Chorea Market Industry is experiencing growth due to the rising prevalence of chorea-related disorders, such as Huntington's disease and Sydenham's chorea. As awareness of these conditions increases, more individuals are being diagnosed, leading to a greater demand for effective treatment options. In 2024, the market is projected to reach 0.8 USD Billion, reflecting the urgent need for innovative therapies. This trend is likely to continue as the global population ages, with the number of affected individuals expected to rise significantly by 2035, when the market could reach 1.67 USD Billion.

    Advancements in Treatment Options

    The Global Chorea Market Industry is benefiting from significant advancements in treatment options, including pharmacological therapies and emerging gene therapies. These innovations are aimed at alleviating symptoms and improving the quality of life for patients. For instance, the development of targeted therapies that address the underlying genetic causes of chorea may revolutionize treatment paradigms. As these therapies gain regulatory approval and become available, they are expected to drive market growth. The anticipated compound annual growth rate (CAGR) of 6.93% from 2025 to 2035 indicates a robust pipeline of new treatments that could reshape the landscape of chorea management.

    Key Companies in the Chorea Market market include

    Industry Developments

      • Spark Therapeutics, Inc. formed a partnership with NeuExcell Therapeutics Inc to develop gene therapy for treating chorea patients.
      • China's national medical products association has approved Austedo, a drug expected to treat Chorea in association with H.D. by Teva pharmaceutical industries LTD. The company is expanding its patient base and revenue by geographical expansion.
      • The company Voyager Therapeutics, the gene therapy company, has now appointed AI Sandrock, the reputed researcher who spent almost half of his career overseeing the clinical development activities at Biogen as CEO.

    Report Overview 

    Future Outlook

    Chorea Market Future Outlook

    The Global Chorea Market is projected to grow at a 6.93% CAGR from 2024 to 2035, driven by advancements in treatment options, increasing awareness, and rising prevalence of chorea-related disorders.

    New opportunities lie in:

    • Develop innovative gene therapies targeting genetic causes of chorea.
    • Expand telehealth services for remote patient monitoring and support.
    • Invest in partnerships with research institutions for drug development and clinical trials.

    By 2035, the Chorea Market is expected to achieve substantial growth, reflecting enhanced treatment modalities and increased patient engagement.

    Market Segmentation

    Report Overview

    • Surgery therapy
    • Medication 
    • Others
    • Clinics
    • Hospitals 
    • Surgical care
    • Medical care
    • Others.
    • Ambulatory surgical centers 
    • Hospitals
    • Clinics  
    • The Middle East and Africa
    • South America
    • Asia Pacific
    • Europe 
    • North America

    Key Industrial Segments

    • Surgery therapy
    • Medication 
    • Others
    • Clinics
    • Hospitals 
    • Surgical care
    • Medical care
    • Others.
    • Ambulatory surgical centers 
    • Hospitals
    • Clinics  
    • The Middle East and Africa
    • South America
    • Asia Pacific
    • Europe 
    • North America

    On the basis of regions

    • The Middle East and Africa
    • South America
    • Asia Pacific
    • Europe 
    • North America

    Recent Market Developments

    • The company Voyager Therapeutics, the gene therapy company, has now appointed AI Sandrock, the reputed researcher who spent almost half of his career overseeing the clinical development activities at Biogen as CEO.
    • China's national medical products association has approved Austedo, a drug expected to treat Chorea in association with H.D. by Teva pharmaceutical industries LTD. The company is expanding its patient base and revenue by geographical expansion.
    • Spark Therapeutics, Inc. formed a partnership with NeuExcell Therapeutics Inc to develop gene therapy for treating chorea patients.
    • Surgery therapy
    • Medication 
    • Others
    • Clinics
    • Hospitals 
    • Surgical care
    • Medical care
    • Others.
    • Ambulatory surgical centers 
    • Hospitals
    • Clinics  
    • The Middle East and Africa
    • South America
    • Asia Pacific
    • Europe 
    • North America

    On the basis of treatment 

    • Surgical care
    • Medical care
    • Others.
    • Ambulatory surgical centers 
    • Hospitals
    • Clinics  
    • The Middle East and Africa
    • South America
    • Asia Pacific
    • Europe 
    • North America

    On the basis of product type

    • Surgery therapy
    • Medication 
    • Others
    • Clinics
    • Hospitals 
    • Surgical care
    • Medical care
    • Others.
    • Ambulatory surgical centers 
    • Hospitals
    • Clinics  
    • The Middle East and Africa
    • South America
    • Asia Pacific
    • Europe 
    • North America

    Key Players in the Chorea Market 

    • S.A. 
    • SOM Innovation Biotech
    • Prana Biotechnology Ltd.
    • Vertex Pharmaceuticals, Inc.
    • RespireRx Pharmaceuticals Inc.
    • Alnylam Pharmaceuticals Inc.
    • Ipsen
    • H. Lundbeck A/S
    • PLC
    • LivaNova
    • Teva Pharmaceutical Industries Ltd.
    • Bausch Health Companies Inc.
    • GlaxoSmithKline plc.
    • Pfizer Inc.
    • ALEVA NEUROTHERAPEUTICS SA
    • Boston Scientific Corporation
    • Medtronic plc.
    • The company Voyager Therapeutics, the gene therapy company, has now appointed AI Sandrock, the reputed researcher who spent almost half of his career overseeing the clinical development activities at Biogen as CEO.
    • China's national medical products association has approved Austedo, a drug expected to treat Chorea in association with H.D. by Teva pharmaceutical industries LTD. The company is expanding its patient base and revenue by geographical expansion.
    • Spark Therapeutics, Inc. formed a partnership with NeuExcell Therapeutics Inc to develop gene therapy for treating chorea patients.
    • Surgery therapy
    • Medication 
    • Others
    • Clinics
    • Hospitals 
    • Surgical care
    • Medical care
    • Others.
    • Ambulatory surgical centers 
    • Hospitals
    • Clinics  
    • The Middle East and Africa
    • South America
    • Asia Pacific
    • Europe 
    • North America

    On the basis of end-user or application

    • Others.
    • Ambulatory surgical centers 
    • Hospitals
    • Clinics  
    • The Middle East and Africa
    • South America
    • Asia Pacific
    • Europe 
    • North America

    On the basis of the end-user application

    • Others
    • Clinics
    • Hospitals 
    • Surgical care
    • Medical care
    • Others.
    • Ambulatory surgical centers 
    • Hospitals
    • Clinics  
    • The Middle East and Africa
    • South America
    • Asia Pacific
    • Europe 
    • North America

    Report Scope

    Attribute/Metric Details
    Market Size 2023 USD 0.74 Billion
    Market Size 2024 USD 0.80 Billion
    Market Size 2032 USD 1.39 Billion
    CAGR 6.34% (2024 - 2032)
    Base Year   2023
    Forecast Period   2024 - 2032
    Historical Data   2022
    Forecast Units   Value (USD Billion)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Segments Covered Types, end user, Region
    Geographies Covered America, Europe, Asia Pacific, Middle East and Africa
    Key Vendors Medtronic plc., Boston Scientific Corporation, ALEVA NEUROTHERAPEUTICS SA, Pfizer Inc., GlaxoSmithKline plc., Bausch Health Companies Inc., Teva Pharmaceutical Industries Ltd., LivaNova, PLC, H. Lundbeck A/S, Ipsen, Alnylam Pharmaceuticals Inc., RespireRx Pharmaceuticals Inc., Vertex Pharmaceuticals, Inc., Prana Biotechnology Ltd., and SOM Innovation Biotech, S.A.

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment
    Download Free Sample

    Kindly complete the form below to receive a free sample of this Report

    Case Study
    Chemicals and Materials